Molecular subtype demonstrated inferior survival among triple‐negative and HER2‐enriched subtypes relative to luminal A and B. Finally, facility type was associated with survival, with patients treated at ARP and integrated network cancer program (INCP) centers showing less favorable outcomes compared with those treated at CCCP or community cancer program (CCP) facilities. This evidence concerns the gene ERBB2 and cancer.